Back to funds
View filing
Knott David M Jr
hedge fundUpdated 30 days agoManaged by Knott David M Jr • Latest filing Q2 2026
Portfolio value
$189.2M
Q2 2026
Filings
14
Quarterly 13F history
Top-10 concentration
100.0%
Weight of largest holdings
Annualized return
-5.8%
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 14 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q1 2023 | $254.5M |
| Q2 2023 | $251.3M |
| Q3 2023 | $261.9M |
| Q4 2023 | $261.6M |
| Q1 2024 | $282.8M |
| Q2 2024 | $250.6M |
| Q3 2024 | $284.6M |
| Q4 2024 | $276.5M |
| Q1 2025 | $212M |
| Q2 2025 | $220.6M |
| Q3 2025 | $248M |
| Q4 2025 | $215.9M |
| Q1 2026 | $168M |
| Q2 2026 | $189.2M |
Top holdings
86 positions as of Q2 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | G GOOGN Alphabet Inc-Cl C | $32.2M | 91.2K | 17.03% | — |
| 2 | A APOS Apollo Global Management, Inc. | $26.6M | 225.0K | 14.07% | — |
| 3 | S SNDX Syndax Pharmaceutical, Inc. | $9.6M | 437.2K | 5.05% | — |
| 4 | X XERS Xeris Biopharma Holdings, Inc. | $8.4M | 1.06M | 4.44% | — |
| 5 | T TVTX Travere Therapeutics, Inc. | $8.4M | 147.3K | 4.42% | — |
| 6 | P PB Protagonist Therapeutics, Inc | $7.7M | 63.0K | 4.08% | — |
| 7 | B BBIO Bridgebio Pharma, Inc. | $6.9M | 92.8K | 3.66% | — |
| 8 | J JPM-PM Iovance Biotherapeutics, Inc. | $6.7M | 1.60M | 3.52% | — |
| 9 | A ALKS Alkermes PLC | $6.4M | 121.8K | 3.37% | — |
| 10 | J JPM-PM JPMorgan Chase & Co. | $5.9M | 18.1K | 3.13% | — |
| 11 | N NOC Janus Henderson AAA CLO ETF | $4.7M | 93.5K | 2.50% | — |
| 12 | L LPLA LPL Financial Holdings Inc. | $4.6M | 16.5K | 2.46% | — |
| 13 | C COGT Cogent Biosciences Inc. | $4.3M | 111.1K | 2.27% | — |
| 14 | T TGTX TG Therapeutics, Inc. | $3.7M | 66.8K | 1.94% | — |
| 15 | ? N/A Catalyst Pharmaceuticals, Inc. | $3.6M | 114.0K | 1.89% | — |
| 16 | M MGRB Agios Pharmaceutical, Inc. | $3.5M | 95.1K | 1.86% | — |
| 17 | V VRDN Viridian Therapeutics, Inc. | $3.3M | 181.0K | 1.76% | — |
| 18 | R RLMD Relmada Therapeutics, Inc. | $3.1M | 451.0K | 1.65% | — |
| 19 | R RCUS Arcus Biosciences, Inc. | $2.5M | 81.2K | 1.32% | — |
| 20 | H HELP Cybin Inc | $2.4M | 370.0K | 1.29% | — |